Nanofiber compositions for a vaccine adjuvant, porous scaffold or porous membrane

Patent metadata

Field	Value
Publication number	US-2024374717-A1
Application number	US-202418783076-A
Country	US
Kind code	A1
Filing date	Jul 24, 2024
Priority date	May 17, 2019
Publication date	Nov 14, 2024
Grant date	—

Abstract

An aspect is directed to a vaccine adjuvant including a nanofiber that comprises an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn. Another aspect is directed to a porous scaffold or a porous membrane that comprises nanofibers comprising an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn, where the porous scaffold or the porous membrane is configured for use in an environment where the nanofibers are exposed to a direct contact with extracellular body fluids.

First claim

1 . A vaccine, comprising:
an antigen; and an adjuvant, wherein: the adjuvant comprises a plurality of nanofibers; the plurality of nanofibers comprises one or more agglomerated nanofibers or one or more individual nanofibers or a combination thereof; the plurality of nanofibers comprises one or more inorganic metal salts selected from: Al, Ca, Mg, Li, K, and Na; the plurality of nanofibers comprises at least one nanofiber that exhibits:
an elastic modulus in a range from around 0.3 GPa to around 300.0 GPa,
a flexural modulus in a range from around 0.3 GPa to around 300.0 GPa,
a flexural strength in a range from around 0.5 MPa to around 5 GPa,
a tensile strength in a range from around 10 MPa to around 30 GPa,
a bending fracture toughness in a range from around 0.05 MPa·m 1/2 to around 50 MPa·m 1/2 ,
a diameter in a range from around 1 nm to around 500 nm,
a length in a range from around 250 nm to around 500 μm, and
an aspect ratio from around 1:10 to around 10,000; and
a total weight fraction of the plurality of nanofibers relative to all other inorganic metal oxides or inorganic metal salts in the adjuvant ranges from around 10 wt. % to around 100 wt. %.

2 . The vaccine of claim 1 , wherein the one or more inorganic metal salts comprises the Li.

3 . The vaccine of claim 1 , wherein the one or more inorganic metal salts comprises the Mg.

4 . The vaccine of claim 1 , wherein the one or more inorganic metal salts comprises the Ca.

5 . The vaccine of claim 1 , wherein the plurality of nanofibers comprises a polymer.

6 . The vaccine of claim 1 , wherein the length of the at least one nanofiber is in a range from around 500 nm to around 20 μm.

7 . The vaccine of claim 1 , wherein the length of the at least one nanofiber is in a range from around 20 μm to around 200 μm.

8 . The vaccine of claim 1 , wherein the at least one nanofiber exhibits a Brunauer-Emmett-Teller (BET) specific surface area (SSA) in a range from around 20 m 2 /g to around 250 m 2 /g.

9 . The vaccine of claim 1 , wherein the at least one nanofiber exhibits a Brunauer-Emmett-Teller (BET) specific surface area (SSA) in a range from around 250 m 2 /g to around 4000 m 2 /g.

10 . The vaccine of claim 1 , wherein the at least one nanofiber comprises one or more internal pores.

11 . The vaccine of claim 10 , wherein a total internal pore volume of the at least one nanofiber is in a range from around 0.01 cm 3 /g to around 3.00 cm 3 /g.

12 . The vaccine of claim 1 , wherein at least about 50 vol. % of a total pore volume of the at least one nanofiber exhibits pore sizes in a range from around 0.30 nm to 60.0 nm.

13 . The vaccine of claim 1 , wherein an average pore size of the at least one nanofiber is in a range from around 0.5 nm to around 50 nm.

14 . The vaccine of claim 13 , wherein the average pore size is in a range from around 5 nm to around 20 nm.

15 . The vaccine of claim 1 , wherein an average pore size of the at least one nanofiber is from around one time to about five times a size of the antigen.

16 . The vaccine of claim 1 , wherein the at least one nanofiber comprises nanocrystalline grains.

17 . The vaccine of claim 16 , wherein an average grain size of the nanocrystalline grains is in a range from around 1 nm to around 100 nm.

18 . The vaccine of claim 16 , wherein the nanocrystalline grains exhibit one or more crystal structures selected from: cubic, tetragonal, monoclinic, orthorhombic and hexagonal.

19 . The vaccine of claim 1 , wherein the at least one nanofiber comprises one or more metal organic frameworks (MOFs).

20 . The vaccine of claim 19 , wherein the one or more MOFs comprises one or more of: Al, Mg, Ca, K, Na, Fe, Y and La.

21 . The vaccine of claim 1 , wherein the one or more inorganic metal salts comprise one or more of:
(i) a metal oxide, (ii) a metal hydroxide, (iii) a metal oxyhydroxide, (iv) a metal sulfate, (v) a metal carbide, (vi) a metal phosphate, (vii) a metal hydroxy phosphate, (viii) a metal hydroxy phosphate sulfate, (ix) a metal phosphate sulfate, (x) a metal carbonate, (xi) a metal carbonate phosphate, (xii) a metal hydroxy sulfate.

22 . A vaccine, comprising:
an adjuvant, wherein: the adjuvant comprises a plurality of nanofibers; the plurality of nanofibers comprises one or more agglomerated nanofibers or one or more individual nanofibers or a combination thereof; the plurality of nanofibers comprises one or more inorganic metal salts selected from: Al, Ca, Mg, Li, K, and Na; and some or all of the plurality of nanofibers is configured to be reduced by dissolution into a body fluid composition in response to exposure to the body fluid composition.

23 . The vaccine of claim 22 , wherein the body fluid composition comprises blood plasma, lymph fluid, interstitial fluid, transcellular fluid, or any combination thereof.

24 . The vaccine of claim 22 , wherein the plurality of nanofibers is configured to be reduced by about 10% to about 100% from around 2 days to around 60 days after the exposure to the body fluid composition.

25 . A vaccine, comprising:
an adjuvant, wherein: the adjuvant comprises a plurality of nanofibers; the plurality of nanofibers comprises one or more agglomerated nanofibers or one or more individual nanofibers or a combination thereof; the plurality of nanofibers comprises one or more inorganic metal salts selected from: Al, Ca, Mg, Li, K, and Na; and wherein a Brunauer-Emmett-Teller (BET) specific surface area (SSA) of the plurality of nanofibers is configured to change in response to exposure to a body fluid composition.

26 . The vaccine of claim 25 , wherein the body fluid composition comprises blood plasma, lymph fluid, interstitial fluid, transcellular fluid, or any combination thereof.

27 . The vaccine of claim 25 , wherein the one or more inorganic metal salts comprise one or more of:
(i) a metal oxide, (ii) a metal hydroxide, (iii) a metal oxyhydroxide, (iv) a metal sulfate, (v) a metal carbide, (vi) a metal phosphate, (vii) a metal hydroxy phosphate, (viii) a metal hydroxy phosphate sulfate, (ix) a metal phosphate sulfate, (x) a metal carbonate, (xi) a metal carbonate phosphate, (xii) a metal hydroxy sulfate.

28 . The vaccine of claim 25 , wherein a length of at least one nanofiber of the plurality of nanofibers is in a range from around 500 nm to around 20 μm.

29 . The vaccine of claim 25 , wherein a length of at least one nanofiber of the plurality of nanofibers is in a range from around 20 μm to around 200 μm.

30 . The vaccine of claim 25 , wherein the BET SSA of the plurality of nanofibers prior to exposure to the body fluid composition is in a range from around 20 m 2 /g to around 250 m 2 /g.

31 . The vaccine of claim 25 , wherein the BET SSA of the plurality of nanofibers prior to exposure to the body fluid composition is in a range from around 250 m 2 /g to around 4000 m 2 /g.

Assignees

• Sila Nanotechnologies Inc

Inventors

• Yushin Gleb
• Turcheniuk Kostiantyn
• Kulinski Kyle

Classifications

• A61L2400/12

  Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61K2039/55511

  Organic adjuvants · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title